📊 MAIA Key Takeaways
Is MAIA Biotechnology, Inc. (MAIA) a Good Investment?
MAIA is a pre-revenue biotech company with severe financial distress, burning cash rapidly with negative operating cash flow of -$18.8M while holding minimal cash reserves. The company exhibits unsustainable economics with no revenue generation, massive operating losses (-$24.3M), and deteriorating equity position that threatens viability without immediate capital raise.
MAIA Biotechnology shows the classic high-risk profile of a pre-revenue biotech, but with especially weak fundamentals at this stage: no revenue, large operating and net losses, and deeply negative cash generation. While the balance sheet carries no long-term debt, the combination of minimal equity, very poor returns on assets and equity, and apparent cash scarcity materially weakens financial resilience and increases dependence on external financing.
Why Buy MAIA Biotechnology, Inc. Stock? MAIA Key Strengths
- Minimal long-term debt exposure reduces leverage risk
- Modest current ratio of 1.66x suggests some near-term liquidity buffer
- Recent insider activity indicates ongoing company engagement
- No long-term debt reduces balance sheet leverage risk
- Current and quick ratios above 1.0 suggest near-term liabilities are still covered on paper
- EPS loss improved versus the prior year, indicating some per-share loss moderation
MAIA Stock Risks: MAIA Biotechnology, Inc. Investment Risks
- Zero revenue with $24.3M operating losses creates unsustainable burn rate
- Cash balance reported at $0.00 creates imminent liquidity crisis
- Severely negative ROE (-942.7%) and ROA (-230.8%) indicate capital destruction
- Free cash flow of -$18.8M with no revenue growth pathway in sight
- Stockholders equity of only $2.4M provides minimal buffer for ongoing losses
- Pre-clinical stage biotech with no clear path to revenue within planning horizon
- No revenue base means the business has not yet demonstrated commercial viability
- Large operating and free cash flow losses imply ongoing cash burn and likely financing pressure
- Very low equity base and extremely negative ROE/ROA indicate fragile financial health
Key Metrics to Watch
- Cash burn rate and months of runway remaining
- Clinical trial progress and regulatory milestones
- Upcoming capital raise requirements and terms
- Operating expense management and cash preservation efforts
- Quarterly cash balance and operating cash burn
- Any transition from zero revenue to sustainable collaboration, licensing, or product revenue
MAIA Biotechnology, Inc. (MAIA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
MAIA Biotechnology, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
MAIA Profit Margin, ROE & Profitability Analysis
MAIA vs Healthcare Sector: How MAIA Biotechnology, Inc. Compares
How MAIA Biotechnology, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is MAIA Biotechnology, Inc. Stock Overvalued? MAIA Valuation Analysis 2026
Based on fundamental analysis, MAIA Biotechnology, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
MAIA Biotechnology, Inc. Balance Sheet: MAIA Debt, Cash & Liquidity
MAIA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: MAIA Biotechnology, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.05 indicates the company is currently unprofitable.
MAIA Revenue Growth, EPS Growth & YoY Performance
MAIA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2022 | N/A | -$1.5M | $-0.49 |
| Q2 2022 | N/A | -$1.0M | $-0.40 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
MAIA Biotechnology, Inc. Dividends, Buybacks & Capital Allocation
MAIA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for MAIA Biotechnology, Inc. (CIK: 0001878313)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MAIA
What is the AI rating for MAIA?
MAIA Biotechnology, Inc. (MAIA) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 94% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MAIA's key strengths?
Claude: Minimal long-term debt exposure reduces leverage risk. Modest current ratio of 1.66x suggests some near-term liquidity buffer. ChatGPT: No long-term debt reduces balance sheet leverage risk. Current and quick ratios above 1.0 suggest near-term liabilities are still covered on paper.
What are the risks of investing in MAIA?
Claude: Zero revenue with $24.3M operating losses creates unsustainable burn rate. Cash balance reported at $0.00 creates imminent liquidity crisis. ChatGPT: No revenue base means the business has not yet demonstrated commercial viability. Large operating and free cash flow losses imply ongoing cash burn and likely financing pressure.
What is MAIA's revenue and growth?
MAIA Biotechnology, Inc. reported revenue of $0.0.
Does MAIA pay dividends?
MAIA Biotechnology, Inc. does not currently pay dividends.
Where can I find MAIA SEC filings?
Official SEC filings for MAIA Biotechnology, Inc. (CIK: 0001878313) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MAIA's EPS?
MAIA Biotechnology, Inc. has a diluted EPS of $-0.70.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MAIA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, MAIA Biotechnology, Inc. has a STRONG SELL rating with 94% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MAIA stock overvalued or undervalued?
Valuation metrics for MAIA: ROE of -942.7% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MAIA stock in 2026?
Our dual AI analysis gives MAIA Biotechnology, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MAIA's free cash flow?
MAIA Biotechnology, Inc.'s operating cash flow is $-18.8M, with capital expenditures of N/A.
How does MAIA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -942.7% (avg: 15%), current ratio 1.66 (avg: 2).